Marea Therapeutics targets acromegaly treatment burden with long-acting MAR002 antibody
Daily acromegaly injections face a convenience challenge. Marea’s MAR002 could reset expectations if Phase 1 durability translates.
Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.